This technology is a bispecific antibody comprised of two linked antibody fragments targeting both a host cell membrane and the HIV envelope protein, allowing for targeted neutralization of HIV.
Current methods for preventing and treating HIV infections have made tremendous advancements in recent years largely due to the application of bispecific antibodies, which tether HIV-specific antibodies to specific cellular populations allowing for responses in the presence of weakly expressed antigens. However, these nascent systems have substantial room for optimization such as implementing CrossMab technology, modulating the antibody linker, and selection/engineering of antibodies specific to different cellular membrane proteins for improved localized antibody concentration.
This bispecific antibody is comprised of two linked antibody fragments targeting a cell specific membrane receptor protein and the HIV envelope protein, allowing for improved recognition of weakly expressed HIV antigens and treating HIV infections. Furthermore, this therapeutic can be modified to implement CrossMab technology, increasing localized antibody concentration to compensate for monovalent binding. These bispecific antibodies can also be used prophylactically to prevent future infections.
Patent Issued (US 9,884,905)
IR Proxy99-CIP
Licensing Contact: Kristin Neuman
